Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D)

Table 2 Duration of disease by source at registration with DILT1D study team

T1D duration	Clinics	Internet	Register
Less than 100 days ^a	24 (9%)	33 (12%)	1 (0.4%)
Between 100 days and two years ^b	56 (21%)	85 (31%)	47 (17%)
Two years or more	1 (0.4%)	24 (9%)	1 (0.4%)

^aNewly diagnosed T1D.
^bRecently diagnosed T1D.
Numbers given are of individuals in each group category where data was available (N = 272).

ISSN: 1745-6215